Cytomegalovirus (CMV) MicroRNA Expression in Vivo and Immune Evasion Correlates - Full Text View

Sponsored by:	University of Alberta
Information provided by:	University of Alberta
ClinicalTrials.gov Identifier:	NCT00677482

Purpose

Cytomegalovirus (CMV) is the most common viral infection in patients who have undergone a transplant.Serious infections due to CMV can affect many parts of the body including the lungs, the gut, and the liver. The purpose of this study is to assess how the virus interacts with the patient's immune system, so that in the future it may be possible to develop better ways to prevent and treat the virus infection.

Condition
Transplant

MedlinePlus related topics: Cytomegalovirus Infections

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cohort, Prospective
Official Title:	Cytomegalovirus (CMV) microRNA Expression in Vivo and Immune Evasion Correlates

Further study details as provided by University of Alberta:

Estimated Enrollment:	30
Study Start Date:	April 2008
Estimated Study Completion Date:	April 2009
Estimated Primary Completion Date:	April 2009 (Final data collection date for primary outcome measure)

Groups/Cohorts
1 Solid organ transplant recipients with both asymptomatic CMV viremia, and symptomatic CMV disease are eligible for inclusion in the study. THis includes liver, kidney, heart, pancreas, lung, intestinal and combined transplant recipients.

Show Detailed Description

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

Solid organ tranplant recipients with both asymptomatic CMV viremia and symptomatic CMV disease are eligible for inclusion in the study. This include liver, kidney, heart, pancreas, lung, intestinal and combined transplant recipients.

Criteria

Inclusion Criteria:

Male or female patients who fulfill the following criteria are eligible for inclusion:

Age >=18 years
Solid Organ Transplant Recipients
Documented CMV disease or asymptomatic CMV viremia

Exclusion Criteria:

Unable to comply with protocol

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00677482

Contacts

Contact: Atul Humar, MD

(780) 407-1600

ahumar@ualberta.ca

Locations

Canada, Alberta
University of Alberta Hospital	Recruiting
Edmonton, Alberta, Canada, T6G-2E1
Contact: Atul Humar, MD (780) 407-1600 ahumar@ualberta.ca
Principal Investigator: Atul Humar, MD
Sub-Investigator: Deepali Kumar, MD

Sponsors and Collaborators

University of Alberta

Investigators

Principal Investigator:

Atul Humar, MD

University of Alberta Hospital

More Information

Publications:

Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis. 2004 Dec;4(12):725-38. Review.

Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant. 2005 Feb;5(2):218-27. Review. Erratum in: Am J Transplant. 2005 Mar;5(3):635.

Humar A, Kumar D, Boivin G, Caliendo AM. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis. 2002 Sep 15;186(6):829-33. Epub 2002 Aug 28.

Rasmussen L. Molecular pathogenesis of human cytomegalovirus infection. Transpl Infect Dis. 1999 Jun;1(2):127-34. Review.

Tomasec P, Wang EC, Davison AJ, Vojtesek B, Armstrong M, Griffin C, McSharry BP, Morris RJ, Llewellyn-Lacey S, Rickards C, Nomoto A, Sinzger C, Wilkinson GW. Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141. Nat Immunol. 2005 Feb;6(2):181-8. Epub 2005 Jan 9.

Responsible Party:	University of Alberta Hospital ( Dr. Atul Humar, MD )
Study ID Numbers:	7304
Study First Received:	May 12, 2008
Last Updated:	January 6, 2009
ClinicalTrials.gov Identifier:	NCT00677482 History of Changes
Health Authority:	Canada: Health Canada

Keywords provided by University of Alberta:

liver transplant
lung transplant
kidney transplant
heart transplant
CMV microRNA

Study placed in the following topic categories:

Virus Diseases
Cytomegalic Inclusion Disease
Cytomegalovirus Infections

DNA Virus Infections
Cytomegalovirus
Herpesviridae Infections

Additional relevant MeSH terms:

Virus Diseases
Cytomegalovirus Infections
DNA Virus Infections
Herpesviridae Infections

ClinicalTrials.gov processed this record on May 07, 2009